Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candidate through clinical trials for a muscle disease and cancers.
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM). The company also announced that they expect to have review of the sentinel cohort safety data by an independent Data Safety Monitoring Board (DSMB) by the end of this year. The Phase 2/3 study is designed as a randomized, double-blind, placebo-controlled multicenter study. Upon favorable review by the DSMB, the study will progress with the main purpose of evaluating the efficacy, safety, and tolerability of two dose levels of ABC008 compared with placebo in subjects with IBM.
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of a Phase 1/2 dose escalation trial to evaluate the safety, tolerability, and proof-of-concept of ABC008 in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer from anemia and/or neutropenia. ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory T cells, central memory T cells, and other immune cells.
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells, will present initial results from a Phase 1 open-label trial of ABC008 in inclusion body myositis (IBM) at American College of Rheumatology Convergence 2021. ABC008, a first-in-class monoclonal antibody, binds KLRG1 (killer cell lectin-like receptor G1), a marker for highly cytotoxic T cells. In the first cohort of individuals with IBM, selective and sustained depletion of highly cytotoxic T cells coincided with early signals of functional improvement. The abstract can be viewed here.
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies.
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held virtually October 19-23, 2021.
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, and ImaginAb, a market leading global provider in immune-oncology imaging agents, today shared initial results of a study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis (IBM). IBM is an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability.
Abcuro is targeting KLRG1 to deplete T cells in autoimmune patients and reactivate inhibited cytotoxic T and NK cells in cancer patients.